Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders

Basit Öğe Kaydı
dc.authorid0000-0002-8892-0439
dc.authorscopusid29067508300
dc.authorscopusid55365316700
dc.authorwosidAlbayrak, Yakup/ABA-7651-2020
dc.authorwosidHashimoto, Kenji/I-5800-2015
dc.contributor.authorAlbayrak, Yakup
dc.contributor.authorHashimoto, Kenji
dc.coverage.doi10.1007/978-3-319-50174-1
dc.date.accessioned2022-05-11T14:41:06Z
dc.date.available2022-05-11T14:41:06Z
dc.date.issued2017
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Ruh Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractAccumulating evidence suggests that sigma-1 receptors play a role in the pathophysiology of neuropsychiatric diseases, as well as in the mechanisms of some selective serotonin reuptake inhibitors (SSRIs). Among the SSRIs, the order of affinity for sigma-1 receptors is as follows: fluvoxamine > sertraline > fluoxetine > escitalopram > citalopram >> paroxetine. Some SSRIs (e.g., fluvoxamine, fluoxetine and escitalopram) and other drugs (donepezil, ifenprodil, dehydroepiandeterone (DHEA)) potentiate nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, and these effects could be antagonized by the selective sigma-1 receptor antagonist NE-100. Furthermore, fluvoxamine, donepezil, and DHEA, but not paroxetine or sertraline, improved phencyclidine-induced cognitive deficits in mice, and these effects could be antagonized by NE-100. Several clinical studies showed that sigma-1 receptor agonists such as fluvoxamine and ifenprodil could have beneficial effects in patients with neuropsychiatric disorders. In this chapter, the authors will discuss the role of sigma-1 receptors in the mechanistic action of some SSRIs, donepezil, neurosteroids, and ifenprodil, and the clinical implications for sigma-1 receptor agonists.
dc.identifier.doi10.1007/978-3-319-50174-1_11
dc.identifier.endpage161
dc.identifier.isbn978-3-319-50174-1
dc.identifier.isbn978-3-319-50172-7
dc.identifier.issn0065-2598
dc.identifier.issn2214-8019
dc.identifier.pmid28315270
dc.identifier.scopus2-s2.0-85015900607
dc.identifier.scopusqualityQ3
dc.identifier.startpage153
dc.identifier.urihttps://doi.org/10.1007/978-3-319-50174-1_11
dc.identifier.urihttps://hdl.handle.net/20.500.11776/9063
dc.identifier.volume964
dc.identifier.wosWOS:000412315600012
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAlbayrak, Yakup
dc.language.isoen
dc.publisherSpringer International Publishing Ag
dc.relation.ispartofSigma Receptors: Their Role in Disease and As Therapeutic Targets
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDonepezil
dc.subjectIfenprodil
dc.subjectFluvoxamine
dc.subjectPsychiatric diseases
dc.subjectSerotonin Reuptake Inhibitors
dc.subjectImproved Cognitive Impairments
dc.subjectPositron-Emission-Tomography
dc.subjectH-3 Ifenprodil Binding
dc.subjectDouble-Blind
dc.subjectDelusional Depression
dc.subjectSchizophrenia Report
dc.subjectTardive-Dyskinesia
dc.subjectNeurite Outgrowth
dc.subjectTherapeutic Drugs
dc.titleSigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders
dc.typeBook Chapter

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
9063.pdf
Boyut:
267.3 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu